Quick Answer
Denali Therapeutics Inc. reported Earnings Per Share Diluted of $2.97 (loss) per share for the year ending 2025.
- Denali Therapeutics Inc. showed a decrease of -15.6% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.55 (loss) per share | Q2 2020: $0.56 (loss) per share | Q3 2020: $0.54 (loss) per share | Q1 2021: $0.58 (loss) per share | Q2 2021: $0.50 (loss) per share | Q3 2021: $0.69 (loss) per share | Q1 2022: $0.53 (loss) per share | Q2 2022: $0.48 (loss) per share | Q3 2022: $0.84 (loss) per share | Q1 2023: $0.80 (loss) per share | Q2 2023: $1.30 per share | Q3 2023: $0.72 (loss) per share | Q1 2024: $0.68 (loss) per share | Q2 2024: $0.59 (loss) per share | Q3 2024: $0.63 (loss) per share | Q1 2025: $0.78 (loss) per share | Q2 2025: $0.72 (loss) per share | Q3 2025: $0.74 (loss) per share.
- Over the full 8 years of available data (2018 to 2025), Denali Therapeutics Inc.'s Earnings Per Share Diluted has declined by 661.5%.
- Historical annual values: Fiscal year 2025: $2.97 (loss) per share | Fiscal year 2024: $2.57 (loss) per share | Fiscal year 2023: $1.06 (loss) per share | Fiscal year 2022: $2.60 (loss) per share | Fiscal year 2021: $2.39 (loss) per share | Fiscal year 2020: $0.63 per share | Fiscal year 2019: $2.07 (loss) per share | Fiscal year 2018: $0.39 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: